Tietge Uwe J F, Selberg Oliver, Kreter Andreas, Bahr Matthias J, Pirlich Matthias, Burchert Wolfgang, Müller Manfred J, Manns Michael P, Böker Klaus H W
Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany.
Liver Transpl. 2004 Aug;10(8):1030-40. doi: 10.1002/lt.20147.
With increasing long-term survival rates after orthotopic liver transplantation (OLT), metabolic alterations complicating the clinical course, such as diabetes mellitus (DM), become increasingly important. Liver cirrhosis is associated with severe alterations in glucose metabolism. However, it is currently unclear whether these changes are reversed by successful OLT. We therefore characterized glucose metabolism in patients with liver cirrhosis and normal fasting glucose levels before OLT (cir), in the clinically stable long-term course after OLT (OLT), and control subjects (con) using oral glucose tolerance tests (cir = 100, OLT = 62, con = 32), euglycemic-hyperinsulinemic clamps (cir = 10, OLT = 27, con = 14), and positron emission tomography (PET) scan analysis with 18F-fluorodeoxyglucose (FDG) as a tracer (cir = 7, OLT = 7, con = 5). Fasting insulin and C-peptide levels were significantly elevated in patients with liver cirrhosis compared with both control subjects (P <.001) and patients after OLT (P <.001). After OLT, insulin was normalized, whereas C-peptide remained elevated (P < 0.01). In the patients with liver cirrhosis, 27% had a normal glucose tolerance, 38% had an impaired glucose tolerance (IGT), and 35% were diabetic. After OLT, 34% had a normal glucose tolerance, 29% an IGT, and 37% were diabetic. Comparison of the same patients before and after OLT demonstrated that IGT or diabetes before OLT was the major risk factor for these conditions after OLT, which was independent of either immunosuppression (cyclosporine vs FK506) or low-dose prednisolone. Total glucose uptake was reduced in patients with liver cirrhosis to less than half the values in control subjects (21.2 +/- 2.8 vs 43.7 +/- 2.4 micromol/kg/minute, respectively, P <.001), whereas patients after OLT showed intermediate values (35.7 +/- 1.4 micromol/kg/minute, P < 0.05 vs con, P < 0.01 vs cir). This difference was caused by a reduction in nonoxidative glucose metabolism in patients with liver cirrhosis compared with control subjects (7.4 +/- 1.9 vs 28.7 +/- 1.8 micromol/kg/minute, respectively, P <.01) and patients after OLT (20.1 +/- 1.4 micromol/kg/minute, P < 0.05 vs con and OLT). In the PET study, skeletal muscle glucose uptake was significantly reduced in patients with liver cirrhosis compared with control subjects (3.5 +/- 0.4 vs 11.8 +/- 2.5 micromol/100g/minute, respectively, P <.05). After OLT, muscle glucose uptake improved compared with patients with liver cirrhosis (5.9 +/- 1.0 micromol/100g/minute, P <.05) but remained significantly lower than in control subjects (P <.05). In conclusion, these results demonstrate that preexisting IGT or diabetes are the major risk factors for IGT and diabetes after OLT. This finding was independent of the immunosuppressive medication. The peripheral insulin resistance in cirrhosis is characterized by a decrease in nonoxidative glucose disposal that is improved, but not normalized, after OLT.
随着原位肝移植(OLT)后长期生存率的提高,诸如糖尿病(DM)等使临床病程复杂化的代谢改变变得越来越重要。肝硬化与葡萄糖代谢的严重改变有关。然而,目前尚不清楚这些变化是否会因OLT成功而逆转。因此,我们通过口服葡萄糖耐量试验(肝硬化组 = 100例,OLT组 = 62例,对照组 = 32例)、正常血糖 - 高胰岛素钳夹试验(肝硬化组 = 10例,OLT组 = 27例,对照组 = 14例)以及以18F - 氟脱氧葡萄糖(FDG)作为示踪剂的正电子发射断层扫描(PET)扫描分析(肝硬化组 = 7例,OLT组 = 7例,对照组 = 5例),对OLT前空腹血糖水平正常的肝硬化患者(cir)、OLT后临床稳定的长期病程患者(OLT)以及对照受试者(con)的葡萄糖代谢进行了特征分析。与对照受试者(P <.001)和OLT后患者(P <.001)相比,肝硬化患者的空腹胰岛素和C肽水平显著升高。OLT后,胰岛素水平恢复正常,而C肽水平仍升高(P < 0.01)。在肝硬化患者中,27%葡萄糖耐量正常,38%葡萄糖耐量受损(IGT),35%患有糖尿病。OLT后,34%葡萄糖耐量正常,29% IGT,37%患有糖尿病。对同一患者OLT前后的比较表明,OLT前的IGT或糖尿病是OLT后出现这些情况的主要危险因素,这与免疫抑制(环孢素与FK506)或低剂量泼尼松龙无关。肝硬化患者的总葡萄糖摄取量降至对照组的一半以下(分别为21.2±2.8与43.7±2.4微摩尔/千克/分钟,P <.001),而OLT后患者的值处于中间水平(35.7±1.4微摩尔/千克/分钟,与对照组相比P < 0.05;与肝硬化组相比P < 0.01)。这种差异是由于肝硬化患者与对照受试者相比非氧化葡萄糖代谢减少(分别为7.4±1.9与28.7±1.8微摩尔/千克/分钟,P <.01),且与OLT后患者相比也减少(20.1±1.4微摩尔/千克/分钟,与对照组和OLT组相比P < 0.05)。在PET研究中,与对照受试者相比,肝硬化患者骨骼肌的葡萄糖摄取显著减少(分别为3.5±0.4与11.8±2.5微摩尔/100克/分钟,P <.05)。OLT后,与肝硬化患者相比,肌肉葡萄糖摄取有所改善(5.9±1.0微摩尔/100克/分钟,P <.05),但仍显著低于对照受试者(P <.05)。总之,这些结果表明,OLT前已存在的IGT或糖尿病是OLT后发生IGT和糖尿病的主要危险因素。这一发现与免疫抑制药物无关。肝硬化患者的外周胰岛素抵抗表现为非氧化葡萄糖处置减少,OLT后这种情况有所改善,但未恢复正常。